Provided by Tiger Fintech (Singapore) Pte. Ltd.

Veru Inc.

0.6180
+0.01502.49%
Post-market: 0.6150-0.0030-0.49%17:36 EDT
Volume:1.07M
Turnover:665.76K
Market Cap:90.59M
PE:-2.49
High:0.6350
Open:0.6100
Low:0.6065
Close:0.6030
Loading ...

BRIEF-Veru Reports Positive Safety Results From Phase 2B Quality Study

Reuters
·
28 May

BUZZ-U.S. STOCKS ON THE MOVE-Veru, GameStop, Azul

Reuters
·
28 May

BUZZ-Veru rises as combo drug shows fewer side effects than semaglutide alone in trial

Reuters
·
28 May

Veru Reports Positive Safety Results From Phase 2B Quality Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

THOMSON REUTERS
·
28 May

Veru Inc - Requests End of Phase 2 Meeting With FDA for Phase 3 Regulatory Clarity

THOMSON REUTERS
·
28 May

Veru Inc: Trial Met Its Prespecified Primary Endpoint

THOMSON REUTERS
·
28 May

Veru Inc - Topline Data for Phase 2B Extension Study Expected in Second Quarter

THOMSON REUTERS
·
28 May

Vaccine Stocks Surge with Moderna up 11%

Tiger Newspress
·
20 May

Trump Says He Will Cut Drug Prices by 59%

Reuters
·
12 May

Veru Inc. Reports Progress in Clinical Trials and Financials

TIPRANKS
·
09 May

Veru Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Veru Q2 EPS $(0.05) Beats $(0.06) Estimate

Benzinga
·
08 May

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

THOMSON REUTERS
·
08 May

Press Release: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Dow Jones
·
08 May

Veru Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
06 May

Veru Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
02 May

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

GlobeNewswire
·
01 May

Pharma Stocks Sink After Trump Says "Major" Tariffs Are Coming

Tiger Newspress
·
09 Apr

Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues

Reuters
·
03 Apr

Compass Therapeutics And 2 More Compelling Penny Stocks

Simply Wall St.
·
02 Apr